皮质类固醇治疗咽痛:随机试验的系统综述与Meta分析
该系统综述与Meta分析纳入10项随机对照试验共1426例患者,评估在标准治疗基础上加用皮质类固醇治疗咽痛的获益与危害。单次低剂量皮质类固醇(最常见为口服地塞米松最大剂量10 mg)可使24小时疼痛缓解率提高(RR 2.2,95%CI 1.2至4.3;风险差12.4%;中等质量证据),48小时无痛率提高(RR 1.5,95%CI 1.3至1.8;风险差18.3%;高质量证据)。作者结论认为单次低剂量皮质类固醇可缓解咽痛且不增加严重不良事件。
要点
- 单次低剂量皮质类固醇使24小时疼痛缓解率提高(RR 2.2,95%CI 1.2至4.3;风险差12.4%)。
- 48小时无痛率提高(RR 1.5,95%CI 1.3至1.8;风险差18.3%;高质量证据)。
- 疼痛缓解起效平均提前4.8小时,疼痛完全缓解平均提前11.1小时。
核心结论
- 单次低剂量皮质类固醇可缓解咽痛患者疼痛,且不增加严重不良事件。
- 纳入试验未评估反复急性咽痛发作患者使用较大累积剂量的潜在风险。
研究设计与样本
- 随机对照试验的系统综述与Meta分析,检索Medline、Embase、Cochrane CENTRAL、试验注册库至2017年5月及相关参考文献。
- 纳入标准为在标准临床治疗基础上加用皮质类固醇的随机对照试验,对象为5岁及以上、在急诊和初级保健机构就诊且有急性扁桃体炎、咽炎临床征象或咽痛临床综合征的患者。
- 共纳入10项试验,1426例个体;采用随机效应模型进行Meta分析,以GRADE方法评估证据质量。
主要发现
- 接受单次低剂量皮质类固醇(最常见为口服地塞米松最大剂量10 mg)的患者24小时疼痛缓解可能性为对照的2.2倍(RR 2.2,95%CI 1.2至4.3;风险差12.4%;中等质量证据)。
- 48小时无痛可能性为对照的1.5倍(RR 1.5,95%CI 1.3至1.8;风险差18.3%;高质量证据)。
- 皮质类固醇组疼痛缓解起效时间平均提前4.8小时(95%CI -1.9至-7.8;中等质量),疼痛完全缓解时间平均提前11.1小时(95%CI -0.4至-21.8;低质量)。
- 24小时绝对疼痛减轻(视觉模拟量表0-10)在皮质类固醇组更大(均数差1.3,95%CI 0.7至1.9;中等质量)。
- 10项试验中9项检索了不良事件信息,6项报告无不良效应,3项报告少量不良事件且多为疾病相关并发症,两组发生率相似。
局限性
- 纳入试验未评估反复急性咽痛发作患者使用较大累积剂量的潜在风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To estimate the benefits and harms of using corticosteroids as an adjunct treatment for sore throat.Design Systematic review and meta-analysis of randomised control trials.Data sources Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), trial registries up to May 2017, reference lists of eligible trials, related reviews.Study selection Randomised controlled trials of the addition of corticosteroids to standard clinical care for patients aged 5 or older in emergency department and primary care settings with clinical signs of acute tonsillitis, pharyngitis, or the clinical syndrome of sore throat. Trials were included irrespective of language or publication status.Review methods Reviewers identified studies, extracted data, and assessed the quality of the evidence, independently and in duplicate. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including the selection of outcomes important to patients. Random effects model was used for meta-analyses. Quality of evidence was assessed with the GRADE approach.Results 10 eligible trials enrolled 1426 individuals. Patients who received single low dose corticosteroids (the most common intervention was oral dexamethasone with a maximum dose of 10 mg) were twice as likely to experience pain relief after 24 hours (relative risk 2.2, 95% confidence interval 1.2 to 4.3; risk difference 12.4%; moderate quality evidence) and 1.5 times more likely to have no pain at 48 hours (1.5, 1.3 to 1.8; risk difference 18.3%; high quality). The mean time to onset of pain relief in patients treated with corticosteroids was 4.8 hours earlier (95% confidence interval -1.9 to -7.8; moderate quality) and the mean time to complete resolution of pain was 11.1 hours earlier (-0.4 to -21.8; low quality) than in those treated with placebo. The absolute pain reduction at 24 hours (visual analogue scale 0-10) was greater in patients treated with corticosteroids (mean difference 1.3, 95% confidence interval 0.7 to 1.9; moderate quality). Nine of the 10 trials sought information regarding adverse events. Six studies reported no adverse effects, and three studies reported few adverse events, which were mostly complications related to disease, with a similar incidence in both groups.Conclusion Single low dose corticosteroids can provide pain relief in patients with sore throat, with no increase in serious adverse effects. Included trials did not assess the potential risks of larger cumulative doses in patients with recurrent episodes of acute sore throat.Systematic review registration PROSPERO CRD42017067808.
引用
- Sadeghirad B, Siemieniuk RAC, Brignardello-Petersen R, et al. Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomised trials. BMJ. 2017. PMID: 28931508. doi:10.1136/bmj.j3887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。